Acadia Pharmaceuticals(ACAD)
Focus: Acadia Pharmaceuticals is a public specialty pharma company focused on neurology with a small-molecule portfolio. The company is heavily dependent on NUPLAZID, which represents 97% of revenue.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
47+23 this month
Hot — 53 jobs added in 30d
Net +23 (53 new, 30 removed). Aggressive expansion phase.
Should You Work at Acadia Pharmaceuticals?
AI assessmentAcadia is a turnaround-focused specialty pharma with a dominant but aging cash cow and an unproven pipeline—suitable for professionals seeking high stakes, neurology expertise, and commercial-scale impact, but with elevated job security risk.
Why Work Here
- Peak revenue product NUPLAZID generated $596M in Part D spending (FY2025) with patent protection until 2037-2039, providing stable base for career development.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$726M
Key Products
$596M Part DStable
Peak11.0yr
Flagship product generating 97% of company revenue with 12+ years of patent protection remaining; faces generic competition post-LOE.
Help build intelligence for Acadia Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.